Unveiling Innovative Strategies for Drug...#pharmatechoutlook via Pharma Tech Outlook …arma-consulting.pharmatechoutlook.com/cxo-insights/u… #VRPX

If human data confirms analgesic benefit without drug tolerance or drug-seeking behavior, this formulation may represent a potential broad-spectrum molecule to treat severe pain and CNS disorders. virpaxpharma.com/2023/10/31/vir… #VRPX #pharmaceuticals #pharma #pharmaindustry #pain #cns

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments virpaxpharma.com/2023/11/15/vir… #VRPX #pharmaceuticals #pharma #pharmaindustry #pain #cns #epilepsy

An article published this weekend on Forbes from contributing writer, Larry Light, highlights some key aspects of the Virpax story and investment thesis, and overview of the company's product mix, including Probudur. forbes.com/sites/lawrence… #VRPX #pharmaceuticals #pharma

Virpax today announced that it has received positive, initial results for Probudur™ in an animal study performed by the U.S. Army Institute of Surgical Research (USAISR). The USAISR is the premier research organization for developing solutions for trauma and critical care

Virpax today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™. The study was designed to determine the MTD of free bupivacaine, Probudur, and Probudur plus free bupivacaine when administered as a single subcutaneous injection to the

Our CEO, Gerald Bruce will be presenting at the BIO International Convention in San Diego. The session will take place on Monday, June 3rd in Theater 3. The management team will also host meetings from June 3rd through the 5th. virpaxpharma.com/2024/05/29/vir… #BIO2024 #VRPX

Virpax announced today that it has secured a $2.5 million loan financing from an institutional investor, and an agreement with the investor to negotiate additional funding, with the aim to provide the company flexibility to further fund the development of its non-addictive drugs

Virpax announced today results for a Swine Model pilot study for Probudur, its long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The pharmacokinetics (PK) and safety study of Probudur in the Swine Model was

Our CEO, Gerald W. Bruce, will present and host one-on-one meetings with investors at the Sidoti August Virtual Investor Conference, taking place on August 14-15, 2024. Joining him will be Vinay Shah, CFO. The presentation will begin at 2:30 PM (ET) on Wednesday, August 14th,

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments virpaxpharma.com/2024/08/13/vir… #VRPX #pharmaceuticals #pharma #pharmaindustry #pain #cns #epilepsy